Trusted by the people who use it
What pathologists, researchers, and clinical teams say about working with MedMorphIQ.
I was able to use MedMorphIQ without needing any help. It’s full automation while allowing me to review and make changes, easy visualization of data made it a necessary solution for my everyday use.
Heavy costs sit in the equivocal HER2 cases, the 2+ reads that get reflexed to expensive confirmatory testing. Consistent quantification resolves more of those borderline cases with confidence, so fewer get escalated at all, saving us time, money, and effort.
It fits the way we already work. No scanner, no new hardware, just faster, cleaner biomarker reads straight from the microscope.
The reproducibility is what won me over, the same slide returns the same index every time, which takes a real source of inter-observer variability off the table.
Proof in practice
International impact and clinical validation
A successful collaboration with Dr. Rushreeta Deuri and her team, whose validation work helped shape MedMorphIQ into a reliable, commercially viable solution, bridging clinical relevance with technical design and demonstrating the software’s validity across several cancer cases.
Dr. Deuri featured MedMorphIQ in two LinkedIn posts.
A thoughtful exchange on digital pathology
Sincere thanks to Dr. Declan Fleming and his team for the opportunity to discuss cellular image processing and the broader role of technology in advancing digital pathology workflows, and for the guidance that’s shaping a potential future collaboration.